Kazia Therapeutics Limited ADR (NASDAQ:KZIA) does about 1.95M shares in volume on a normal day but saw 4432169 shares change hands in the recent trading day. The company now has a market cap of 3.93M USD. Its current market price is $1.18, marking an increase of 39.63% compared to the previous close of $0.85. The 52 week high reached by this stock is $15.80 whilst the lowest price level in 52 weeks is $0.76.
Kazia Therapeutics Limited ADR (KZIA) has a 20-day trading average at $0.9171 and the current price is -92.53% off the 52-week high compared with 56.08% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.4516 and its 200-day simple moving average is $3.3871. If we look at the stock’s price movements over the week, volatility stands at 22.60%, which decreases to 14.58% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 52.51 to suggest the stock is neutral.
The consensus objective for the share price is $3.00, suggesting that the stock has a potential upside of 60.67% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 06, 2025 when Maxim Group initiated the stock to “Buy” and issued a price target of $3. H.C. Wainwright initiated its price target at $17.
The current price level is 28.67%, -18.71%, and -65.16% away from its SMA20, SMA50, and SMA200 respectively, with the KZIA price moving above the 50-day SMA on current market day. Kazia Therapeutics Limited ADR (KZIA) stock is up 38.59% over the week and -15.71% over the past month. Its price is -33.33% year-to-date and -46.36% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and -0.05 for whole year.
To reach the target analysts have set, the stock logically needs to grow 60.67 percent from here.
Outstanding shares total 3.33M with insiders holding 0.00% of the shares and institutional holders owning 13.93% of the company’s common stock. The company has a return on equity of -2639.52%. The beta has a value of 2.29. Price to sales ratio is 2.59.
